Home
/
Intellia Therapeutics, Inc.
/
Financials
/
Quarterly
Intellia Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Intellia Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$13.78M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$14.25M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$16.63M
May 8, 2025
Q3
2025
Sep 30, 2024
$9.11M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$6.96M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$28.94M
May 8, 2025
Q3
2024
Sep 30, 2023
$11.99M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$13.59M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$12.61M
May 9, 2024
Q3
2023
Sep 30, 2022
$13.27M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$14.03M
Aug 3, 2023
Q1
2023
Mar 31, 2022
$11.25M
May 4, 2023
Q3
2022
Sep 30, 2021
$7.20M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$6.55M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$6.45M
May 5, 2022
Q3
2021
Sep 30, 2020
$22.22M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$16.26M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$12.92M
May 6, 2021
Q3
2020
Sep 30, 2019
$10.62M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$11.12M
Aug 6, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($101.32M)
Nov 6, 2025
Q3
2025
Jun 30, 2025
($101.26M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($101.26M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($114.33M)
May 8, 2025
Q2
2025
Mar 31, 2025
($114.33M)
Aug 7, 2025
Q3
2025
Mar 31, 2025
($114.33M)
Nov 6, 2025
Q3
2025
Sep 30, 2024
($135.71M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($146.98M)
Aug 7, 2025
Q3
2025
Jun 30, 2024
($146.98M)
Nov 6, 2025
Q1
2025
Mar 31, 2024
($107.44M)
May 8, 2025
Q2
2025
Mar 31, 2024
($107.44M)
Aug 7, 2025
Q3
2025
Mar 31, 2024
($107.44M)
Nov 6, 2025
Q3
2024
Sep 30, 2023
($122.22M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($123.68M)
Aug 8, 2024
Q3
2024
Jun 30, 2023
($123.68M)
Nov 7, 2024
Q2
2024
Mar 31, 2023
($103.13M)
Aug 8, 2024
Q3
2024
Mar 31, 2023
($103.13M)
Nov 7, 2024
Q1
2024
Mar 31, 2023
($103.13M)
May 9, 2024
Q3
2023
Sep 30, 2022
($113.23M)
Nov 9, 2023
Q3
2023
Jun 30, 2022
($100.68M)
Nov 9, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($111.48M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($110.00M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($120.81M)
May 8, 2025
Q3
2025
Sep 30, 2024
($144.77M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($139.04M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($114.00M)
May 8, 2025
Q3
2024
Sep 30, 2023
($131.11M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($132.33M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($111.96M)
May 9, 2024
Q3
2023
Sep 30, 2022
($105.53M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($98.30M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($144.25M)
May 4, 2023
Q3
2022
Sep 30, 2021
($71.99M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($69.02M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($46.43M)
May 5, 2022
Q3
2021
Sep 30, 2020
($28.10M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($33.03M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($33.05M)
May 6, 2021
Q3
2020
Sep 30, 2019
($25.33M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($27.46M)
Aug 6, 2020